- Motley Fool•7 days ago
You have years and years of investing ahead of you, which is why these three companies might belong in your portfolio.
- TheStreet.com•8 days ago
The data to emerge from Novartis' JULIET study is of keen interest to investors because it will be compared against Kite Pharma's competing "CAR-T" KTE-C19 in the same DLBCL patients.
- TheStreet.com•14 days ago
Political negatives keep popping up, forcing us to rethink the Trump trade, says Jim Cramer.
KITE: Summary for Kite Pharma, Inc. - Yahoo Finance
Kite Pharma, Inc. (KITE)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
|Bid||78.10 x 400|
|Ask||82.29 x 500|
|Day's range||80.47 - 83.66|
|52-week range||39.82 - 88.58|
Trade prices are not sourced from all markets
|PE ratio (TTM)||-14.76|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|